Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
₹25 Cr
Revenue (TTM)
₹48 Cr
Net Profit (TTM)
₹-1 Cr
ROE
-14.8 %
ROCE
41.4 %
P/E Ratio
--
P/B Ratio
2.6
Industry P/E
26.59
EV/EBITDA
5.7
Div. Yield
0 %
Debt to Equity
0.2
Book Value
₹12.4
EPS
₹-1.8
Face value
10
Shares outstanding
7,791,300
CFO
₹7.85 Cr
EBITDA
₹3.07 Cr
Net Profit
₹-3.76 Cr
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Gujarat Terce Lab
| -26.5 | -16.7 | -33.7 | -50.4 | 24.3 | 35.4 | 15.6 |
|
BSE Healthcare
| -4.7 | -5.8 | -5.4 | 1.3 | 23.7 | 14.0 | 10.6 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
|---|---|---|---|---|---|---|
|
Gujarat Terce Lab
| -48.5 | 197.0 | 56.1 | 0.1 | 106.9 | 9.6 |
|
BSE Small Cap
| -6.6 | 29.0 | 47.5 | -1.8 | 62.8 | 32.1 |
|
BSE Healthcare
| -3.3 | 43.1 | 37.0 | -12.1 | 20.9 | 61.4 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price (₹) | Market Cap (₹ Cr) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Gujarat Terce Lab
|
32.0 | 24.9 | 48.4 | -1.3 | 7.6 | -17.7 | -- | 2.6 |
| 2,791.2 | 34,920.1 | 5,201.6 | 1,014.6 | 22.9 | 25 | 34.4 | 7.6 | |
| 7,827.5 | 19,544.3 | 2,177.5 | 200.9 | 11.3 | 26.5 | 97.3 | 23.5 | |
| 1,565.8 | 11,917.5 | 2,089.5 | 622.0 | 31.3 | 20.4 | 19.4 | 3.6 | |
| 1,332.1 | 18,429.0 | 3,078.2 | 469.4 | 26.4 | 14.9 | 42.7 | 5.1 | |
| 1,961.1 | 31,410.1 | 4,193.0 | 753.8 | 22.7 | 20.8 | 41.7 | 7.8 | |
| 4,887.1 | 22,333.8 | 2,482.3 | 853.6 | 33.7 | 18.9 | 26.2 | 5.6 | |
| 4,778.6 | 7,918.9 | 1,348.5 | 293.5 | 28.1 | 50.7 | 27 | 11.4 | |
| 388.9 | 7,603.2 | 1,432.0 | 149.0 | 19.1 | 7.9 | 50.7 | 3.1 | |
| 971.2 | 8,938.5 | 4,725.6 | 528.7 | 14.9 | 20.7 | 17.5 | 3.0 |
No Review & Analysis are available.
Gujarat Terce Laboratories Limited manufactures and markets medical and pharmaceutical preparations in India. The company offers branded and generic formulations covering various therapeutic, such as antibiotics, respiratory, nutraceuticals,... gastrointestinal, anti-fungal, and others. It provides its products in various forms, such as tablets, capsules, oral liquids, injections, and ointments. The company also exports its products. Gujarat Terce Laboratories Limited was founded in 1985 and is based in Ahmedabad, India. Read more
Incorporated
1985
Chairman
Natwarbhai P Prajapati
Managing Director
Aalap Prajapati
Headquarters
Gandhinagar, Gujarat
Website
Annual Reports
Announcements
View AnnouncementsThe share price of Gujarat Terce Laboratories Ltd is ₹31.96 (BSE) as of 02-Apr-2026 IST. Gujarat Terce Laboratories Ltd has given a return of 24.25% in the last 3 years.
Since, TTM earnings of Gujarat Terce Laboratories Ltd is negative, P/E ratio is not available.
The P/B ratio of Gujarat Terce Laboratories Ltd is 2.58 times as on 02-Apr-2026, a 43 discount to its peers’ median range of 4.49 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
0.00
|
7.40
|
|
2024
|
161.33
|
5.53
|
|
2023
|
0.00
|
1.80
|
|
2022
|
22.24
|
2.27
|
|
2021
|
0.00
|
0.67
|
The 52-week high and low of Gujarat Terce Laboratories Ltd are Rs 68.40 and Rs 29.00 as of 05-Apr-2026.
Gujarat Terce Laboratories Ltd has a market capitalisation of ₹ 25 Cr as on 02-Apr-2026. As per SEBI classification, it is a Small Cap company.
Before investing in Gujarat Terce Laboratories Ltd, assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.